FDA Rejects Coherus Application For Neulasta Biosimilar
The U.S. Food and Drug Administration has rejected Coherus BioSciences Inc.'s Neulasta biosimilar, the company said Monday, leading to a stock plunge of more than 20 percent....To view the full article, register now.
Already a subscriber? Click here to view full article